Sagimet Biosciences filed an updated slide presentation for investors on October 22, 2026. The company reported a cash balance of $257.6 million as of June 30, 2026, which is expected to fund operations through mid-2029. This runway includes proceeds from a $115 million Series A equity offering completed in September 2026 and covers the readout of the denifanstat Phase 3 AURORA trial for moderate to severe acne, with first patient dosing occurring in October 2026 and top-line results expected in the second half of 2027. The presentation also highlighted that denifanstat met all primary and secondary endpoints in a prior Phase 3 trial conducted by partner Ascletis in China, where an NDA was accepted for review in December 2025. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase inhibitors for dermatological and metabolic diseases.
